Alimera Sciences (NASDAQ:ALIM) Earns Hold Rating from Analysts at began coverage on shares of Alimera Sciences (NASDAQ:ALIMGet Rating) in a research report issued on Wednesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Several other equities analysts have also commented on the company. Zacks Investment Research lowered Alimera Sciences from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 1st. HC Wainwright reduced their price target on Alimera Sciences from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, February 25th. Finally, Alliance Global Partners reduced their price target on Alimera Sciences from $14.50 to $11.00 in a research report on Friday, February 25th.

Shares of NASDAQ:ALIM opened at $5.34 on Wednesday. Alimera Sciences has a 1 year low of $3.94 and a 1 year high of $11.48. The stock has a market capitalization of $37.34 million, a P/E ratio of -6.76 and a beta of 1.61. The stock has a 50-day simple moving average of $5.42 and a 200-day simple moving average of $5.05.

Alimera Sciences (NASDAQ:ALIMGet Rating) last issued its earnings results on Thursday, February 24th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($0.21). The firm had revenue of $13.96 million during the quarter, compared to analyst estimates of $14.00 million. During the same period in the prior year, the firm earned ($0.18) EPS. Research analysts expect that Alimera Sciences will post -1.89 EPS for the current year.

In related news, major shareholder Stanley Morgan sold 250,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 8th. The stock was sold at an average price of $4.55, for a total transaction of $1,137,500.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 13.50% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in ALIM. Morgan Stanley raised its position in shares of Alimera Sciences by 0.7% in the 2nd quarter. Morgan Stanley now owns 428,109 shares of the biopharmaceutical company’s stock valued at $3,896,000 after purchasing an additional 2,797 shares in the last quarter. Ensign Peak Advisors Inc acquired a new position in shares of Alimera Sciences in the 3rd quarter valued at approximately $81,000. Finally, Millennium Management LLC acquired a new position in shares of Alimera Sciences in the 4th quarter valued at approximately $65,000. 28.17% of the stock is currently owned by institutional investors.

Alimera Sciences Company Profile (Get Rating)

Alimera Sciences, Inc, a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.

Featured Stories

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with's FREE daily email newsletter.